Drug intelligence / Profile preview

AFA-281

Development stage: Phase 2
Lead developer: AfaSci
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

AFA-281 is a new chemical entity under development by AfaSci for the treatment of neuropathic pain, inflammatory pain, osteoarthritis, cancer pain, lumbosacral radiculopathy, alcohol use disorder, and cocaine use disorder. It is administered orally or intravenously. The drug acts as a dual modulator by inhibiting both T-type calcium channels (Cav3) and soluble epoxide hydrolase (sEH), targeting mechanisms involved in neuronal excitability and neuroinflammation. Clinical trials are ongoing in Phase I and II for various indications[1][2][3][4][6].

Other names: AFA 281AFA281AFA-281

Targets

EPHX2 (Soluble epoxide hydrolase)CaV3 (Caveolin-3)

Beyond the preview

Go deeper on AFA-281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFA-281.

Explore the full profile